Indication
Refractory Transformed B-cell Non-Hodgkin Lymphoma
3 clinical trials
3 products
4 drugs
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's SyndromeStatus: Recruiting, Estimated PCD: 2025-12-31
Drug
cyclophosphamideProduct
FludarabineProduct
Lisocabtagene MaraleucelDrug
ZanubrutinibClinical trial
Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of RelapseStatus: Not yet recruiting, Estimated PCD: 2026-01-15
Drug
golcadomideClinical trial
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells TherapyStatus: Active (not recruiting), Estimated PCD: 2023-01-10
Product
ObinutuzumabDrug
glofitamab